What is paid in your country
Which medicines are on the public health insurance list, by test result. We only state what a public source confirms, with date and link. Whether a medicine applies to you is decided by your care team with the health insurance fund.
Serbia
Lists B and C of the RFZO health insurance fund, valid from 11 July 2026 · List C (PDF), List B (PDF) · checked on 16 November 2026
| Test result | Medicine | What for (simplified) |
|---|
| EGFR | osimertinib | First treatment for advanced NSCLC with an EGFR mutation; with T790M after an earlier EGFR tablet; after complete surgery (stage IB–IIIA, exon 19 or L858R). |
|---|
| EGFR | gefitinib, erlotinib, afatinib | First treatment, stage IIIb/IV, good general condition. Erlotinib also later in adenocarcinoma. |
|---|
| ALK | alectinib, brigatinib | First treatment for advanced ALK-positive NSCLC. |
|---|
| no EGFR or ALK | pembrolizumab | First treatment: alone if PD-L1 is 50% or more, with chemotherapy if PD-L1 is lower. A few cycles first, then continued only if it works. |
|---|
| no EGFR or ALK | atezolizumab | First treatment alone if PD-L1 is high, or with chemotherapy; also after chemotherapy. |
|---|
| Chemotherapy | carboplatin, cisplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed | Lists B and C. Everything on these lists is fully paid by the fund. |
|---|
How to get the treatment
Three doctors from one of the hospitals below propose the treatment, and the RFZO commission approves it. The list names these hospitals:
- Institut za onkologiju i radiologiju Srbije (Beograd)
- Klinika za pulmologiju, UKC Srbije (Beograd)
- KBC Bežanijska kosa (Beograd)
- Vojnomedicinska akademija (Beograd)
- Institut za plućne bolesti Vojvodine (Sremska Kamenica)
- Klinika za plućne bolesti, UKC Niš
- UKC Kragujevac
Not on the list
Lorlatinib, crizotinib and durvalumab; no medicine against KRAS G12C, ROS1, RET, MET, NTRK or HER2. Dabrafenib and trametinib are listed for melanoma only.
What is not publicly known
A new regulation from July 2026 may come with newer tables. Whether biomarker tests are always paid is not stated in these lists.
Montenegro
Medicines list of the FZOCG health insurance fund, October 2026 · List (PDF), all versions · checked on 16 November 2026
| Test result | Medicine | What for (simplified) |
|---|
| EGFR | osimertinib | First treatment with an EGFR mutation; with T790M; after complete surgery (stage IB–IIIA), up to 36 months. |
|---|
| EGFR | gefitinib | Advanced NSCLC with an EGFR mutation. |
|---|
| ALK | alectinib, brigatinib | First treatment or after crizotinib. |
|---|
| ALK | lorlatinib | First treatment or after earlier ALK tablets. |
|---|
| ALK, ROS1 | crizotinib | For ALK (first treatment or later) and for ROS1. |
|---|
| no EGFR or ALK | pembrolizumab | First treatment: alone if PD-L1 is 50% or more, with chemotherapy if PD-L1 is lower. A few cycles first, then continued only if it works. |
|---|
| no EGFR or ALK | atezolizumab | First treatment alone if PD-L1 is high, or with chemotherapy; also after chemotherapy. |
|---|
| Stage III | durvalumab | After chemoradiotherapy for inoperable stage III, PD-L1 1% or more, up to 12 months. |
|---|
| Chemotherapy | carboplatin, cisplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed | On the list. |
|---|
How to get the treatment
A tumour board proposes the treatment. Usually two cycles are approved first, then the effect is checked. The list names these tumour boards:
- Klinički centar Crne Gore, Klinika za onkologiju i radioterapiju (Podgorica)
- Opšta bolnica Bijelo Polje
- Specijalna bolnica za plućne bolesti Brezovik (Nikšić)
Not on the list
Afatinib, erlotinib, amivantamab; no medicine against KRAS G12C, RET, MET or NTRK. Dabrafenib and trametinib are listed for melanoma only.
Albania
List of the FSDKSH health insurance fund, decision no. 324 of 6 May 2026 · Official Gazette no. 100/2026 (PDF) · checked on 16 November 2026
Cancer medicines are on List I and are dispensed by hospital pharmacies, 90 to 100 percent paid. The 2026 list includes:
- EGFR: osimertinib
- ALK: alectinib, lorlatinib
- BRAF V600E: dabrafenib, trametinib
- Immunotherapy: pembrolizumab, nivolumab, ipilimumab, atezolizumab
The list does not say for which disease a medicine is paid. Your care team clarifies with the fund whether it applies to you.
Not on the list
Chemotherapy, older EGFR tablets, brigatinib, crizotinib, durvalumab, and no medicine against KRAS G12C, ROS1, RET, MET, NTRK or HER2.
What is not publicly known
How hospitals provide chemotherapy and who applies for a treatment is not publicly described. Ask your care team.
Bosnia and Herzegovina
Federation of Bosnia and Herzegovina
Solidarity Fund list (version 47/19, last amended by 76/26) · List (PDF), September 2026 update · checked on 19 November 2026
Hospital cancer medicines are paid by the Solidarity Fund, not the regular medicines list. The list includes standard chemotherapy, erlotinib, crizotinib, alectinib, nivolumab, pembrolizumab, atezolizumab and dabrafenib with trametinib (explicitly as first treatment for advanced NSCLC). Since September 2026 the list names lung cancer explicitly for pembrolizumab and atezolizumab: both as a first treatment alone or with chemotherapy and after complete surgery, pembrolizumab also before surgery, and atezolizumab also for extensive-stage small cell lung cancer.
Not on the list
Osimertinib, lorlatinib, brigatinib, durvalumab, and no medicine against KRAS G12C, RET, MET, NTRK or HER2.
Republika Srpska
The Republika Srpska health insurance fund only publishes its pharmacy lists. Hospital cancer medicines run through a separate list that is not public. Ask your care team or the fund. Fund lists
North Macedonia
FZOM health insurance medicines list, overview of 7 August 2026 (list B, hospital) · FZOM list · checked on 18 November 2026
| Medicine | What for (simplified) |
|---|
| cisplatin, carboplatin, etoposide | On the list. |
|---|
| gemcitabine | First treatment for NSCLC together with cisplatin, 3 to 6 cycles. |
|---|
| paclitaxel | First treatment for NSCLC together with cisplatin, up to 4 cycles. |
|---|
| docetaxel | First treatment for NSCLC together with cisplatin, 3 to 6 cycles; as second treatment in stage III or IV in good general condition, up to 4 cycles. |
|---|
Not on the list
Pemetrexed, vinorelbine, all targeted tablets (EGFR, ALK and others) and immunotherapy. Whether they are paid through other state programmes is not stated in this list.
Kosovo
Which cancer medicines the state provides in Kosovo is currently not publicly available. Public hospitals dispense medicines from the essential medicines list, which the Ministry of Health is revising.
According to the Ministry price list, these are among the medicines authorised in Kosovo: osimertinib, erlotinib, alectinib, lorlatinib, crizotinib, pembrolizumab, nivolumab, atezolizumab, durvalumab. Authorised does not mean paid. Ask the oncology clinic what you have to pay yourself. Price list